Variation within 3'-UTRs of base excision repair genes and response to therapy in colorectal cancer patients: A potential modulation of microRNAs binding

Clinical Cancer Research

Volumn 19, Issue 21, 2013, Pages 6044-6056

  Pardini, Barbara ^a   Rosa, Fabio ^a   Barone, Elisa ^c   Di Gaetano, Cornelia ^a,b   Slyskova, Jana ^e,g   Novotny, Jan ^h   Levy, Miroslav ^f   Garritano, Sonia ^d   Vodickova, Ludmila ^e,g   Buchler, Tomas ^f   Gemignani, Federica ^c   Landi, Stefano ^c   Vodicka, Pavel ^e,g   Naccarati, Alessio ^a,e  

^a Human Genetics Foundation   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF TRENTO   (Italy)

^e Inst of Reproductive Medicine   (Italy)

^f Thomayer Hospital   (Italy)

^g Institute of Biology   (Italy)

^h CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FLUOROURACIL; FOLINIC ACID; MICRORNA;

3' UNTRANSLATED REGION; ADULT; AGED; ALLELE; ARTICLE; BASE EXCISION REPAIR GENE; BINDING SITE; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG RESPONSE; EXCISION REPAIR; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; NEIL2 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; REPORTER GENE; RNA BINDING; SINGLE NUCLEOTIDE POLYMORPHISM; SMUG1 GENE; TUMOR GENE;

3' UNTRANSLATED REGIONS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BINDING SITES; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DNA REPAIR; FEMALE; GENETIC VARIATION; HUMANS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84887061000     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0314     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60: 277-300.
2. Theodoratou E, Montazeri Z, Hawken S, Allum GC, Gong J, Tait V, et al. Systematic meta-analyses and field synopsis of genetic association studies in colorectal cancer. J Natl Cancer Inst 2012;104: 1433-57.
3. Berwick M, Vineis P. Markers ofDNArepair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000;92: 874-97.
4. Wilson DM III, Kim D, Berquist BR, Sigurdson AJ. Variation in base excision repair capacity. Mutat Res 2011;711: 100-12.
5. Wilson DM III, Bohr VA. The mechanics of base excision repair, and its relationship to aging and disease. DNA Repair 2007;6: 544-59.
6. Pardini B, Naccarati A, Novotny J, Smerhovsky Z, Vodickova L, Polakova V, et al. DNA repair genetic polymorphisms and risk of colorectal cancer in the Czech Republic. Mutat Res 2008;638: 146-53.
7. Vodicka P, Stetina R, Polakova V, Tulupova E, Naccarati A, Vodickova L, et al. Association of DNA repair polymorphisms with DNA repair functional outcomes in healthy human subjects. Carcinogenesis 2007; 28: 657-64.
8. Wyatt MD, WilsonDMIII. Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 2009;66: 788-99.
9. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3: 330-8.
10. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136: 215-33.
11. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004;303: 83-6.
12. Xu P, Guo M, Hay BA. MicroRNAs and the regulation of cell death. Trends Genet 2004;20: 617-24.
13. Slattery ML, Wolff E, Hoffman MD, Pellatt DF, Milash B, Wolff RK. MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes Chromosomes Cancer 2011;50: 196-206.
14. Duan S, Mi S, Zhang W, Dolan ME. Comprehensive analysis of the impact of SNPs and CNVs on human microRNAs and their regulatory genes. RNA Biol 2009;6: 412-25.
15. Mishra PJ, Humeniuk R, Longo-Sorbello GS, Banerjee D, Bertino JR. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A 2007;104: 13513-8.
16. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 2007;21: 1132-47.
17. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2008;105: 7269-74.
18. Naccarati A, Pardini B, Landi S, Landi D, Slyskova J, Novotny J, et al. Polymorphisms in miRNA binding sites of nucleotide excision repair genes and colorectal cancer risk. Carcinogenesis 2012;33: 1346-51.
19. Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 2008;29: 579-84.
20. Landi D, Moreno V, Guino E, Vodicka P, Pardini B, Naccarati A, et al. Polymorphisms affecting micro-RNA regulation and associated with the risk of dietary-related cancers: a review from the literature and new evidence for a functional role of rs17281995 (CD86) and rs1051690 (INSR), previously associated with colorectal cancer. Mutat Res 2011;717: 109-15.
21. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009;18: 1688-94.
22. Pardini B, Kumar R, Naccarati A, Prasad RB, Forsti A, Polakova V, et al. MTHFR and MTRR genotype and haplotype analysis and colorectal cancer susceptibility in a case-control study from the Czech Republic. Mutat Res 2011;721: 74-80.
23. Polakova V, Pardini B, Naccarati A, Landi S, Slyskova J, Novotny J, et al. Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. Hum Mutat 2009;30: 661-8.
24. Barenboim M, Zoltick BJ, Guo Y, Weinberger DR. MicroSNiPer: a web tool for prediction of SNP effects on putative microRNA targets. Hum Mutat 2010;31: 1223-32.
25. Sharma V, Misteli T. Non-coding RNAs in DNA damage and repair. FEBS Lett 2013;587: 1832-9.
26. Iorio MV, Croce CM. microRNA involvement in human cancer. Carcinogenesis 2012;33: 1126-33.
27. Slaby O, Bienertova-Vasku J, Svoboda M, Vyzula R. Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer. J Cell Mol Med 2012;16: 8-21.
28. Teo MT, Landi D, Taylor CF, Elliott F, Vaslin L, Cox DG, et al. The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. Carcinogenesis 2012;33: 581-6.
29. Pettersen HS, Visnes T, Vagbo CB, Svaasand EK, Doseth B, Slupphaug G, et al. UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation. Nucleic Acids Res 2011;39: 8430-44.
30. Ingraham HA, Tseng BY, Goulian M. Mechanism for exclusion of 5- fluorouracil from DNA. Cancer Res 1980;40: 998-1001.
31. Wallace SS, Murphy DL, Sweasy JB. Base excision repair and cancer. Cancer Lett 2012;327: 73-89.
32. Kavli B, Sundheim O, Akbari M, Otterlei M, Nilsen H, Skorpen F, et al. hUNG2 is the major repair enzyme for removal of uracil from U:A matches, U:G mismatches, and U in single-stranded DNA, with hSMUG1 as a broad specificity backup. J Biol Chem 2002;277: 39926-36.
33. An Q, Robins P, Lindahl T, Barnes DE. 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity. Cancer Res 2007;67: 940-5.
34. Banerjee D, Mandal SM, Das A, Hegde ML, Das S, Bhakat KK, et al. Preferential repair of oxidized base damage in the transcribed genes of mammalian cells. J Biol Chem 2011;286: 6006-16.
35. Landi D, Gemignani F, Pardini B, Naccarati A, Garritano S, Vodicka P, et al. Identification of candidate genes carrying polymorphisms associated with the risk of colorectal cancer by analyzing the colorectal mutome and microRNAome. Cancer 2012;118: 4670-80.
36. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, et al. The colorectal microRNAome. Proc Natl Acad Sci U S A 2006;103: 3687-92.
37. Boni V, Zarate R, Villa JC, Bandres E, Gomez MA, Maiello E, et al. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J 2011;11: 429-36.
38. Hummel R, Wang T, Watson DI, Michael MZ, Van der Hoek M, Haier J, et al. Chemotherapy-induced modification of microRNA expression in esophageal cancer. Oncol Rep 2011;26: 1011-7.
39. Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 2009;10: 399-416.
40. Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, et al. Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res 2012;18: 3982-91.
41. Wu Y, Xiao Y, Ding X, Zhuo Y, Ren P, Zhou C, et al. A miR-200b/200c/429-binding site polymorphismin the 30 untranslated region of the AP- 2alpha gene is associated with cisplatin resistance. PLoS ONE2011;6: e29043.
42. Haas U, Sczakiel G, Laufer SD. MicroRNA-mediated regulation of gene expression is affected by disease-associated SNPs within the 30-UTR via altered RNA structure. RNA Biol 2012;9: 924-37.